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SUMMARY
Induced pluripotent stem cell (iPSC)-derived dopa-
mine neurons provide an opportunity to model Par-
kinson’s disease (PD), but neuronal cultures are
confounded by asynchronous and heterogeneous
appearance of disease phenotypes in vitro. Using
high-resolution, single-cell transcriptomic analyses
of iPSC-derived dopamine neurons carrying the
GBA-N370S PD risk variant, we identified a progres-
sive axis of gene expression variation leading to
endoplasmic reticulum stress. Pseudotime analysis
of genes differentially expressed (DE) along this
axis identified the transcriptional repressor histone
deacetylase 4 (HDAC4) as an upstream regulator of
disease progression. HDAC4 was mislocalized to
the nucleus in PD iPSC-derived dopamine neurons
and repressed genes early in the disease axis, lead-
ing to late deficits in protein homeostasis. Treatment
of iPSC-derived dopamine neurons with HDAC4-
modulating compounds upregulated genes early in
the DE axis and corrected PD-related cellular pheno-
types. Our study demonstrates how single-cell tran-
scriptomics can exploit cellular heterogeneity to
reveal disease mechanisms and identify therapeutic
targets.
INTRODUCTION
Parkinson’s disease (PD) is a neurodegenerative disorder
affecting over 6 million people worldwide, predominantly over
the age of 65 (Baker and Graham, 2004). PD is characterized
by motor symptoms, including rigidity, resting tremor, bradyki-
nesia, and postural instability, and non-motor features, including
cognitive impairments, anxiety, and depression (Gonera et al.,
1997). The motor symptoms are due to the progressive loss of
dopamine neurons in the substantia nigra pars compacta, with
approximately 50% of dopamine neurons lost in the midbrain
at the onset of motor symptoms (Fearnley and Lees, 1991).
The majority of PD cases are idiopathic, with only about 10%
attributed to inherited PD cases. The glucocerebrosidase gene
encodes the lysosomal enzyme, GCase, homozygous mutations
in which cause the autosomal recessive lysosomal storage dis-
order, Gaucher’s disease (GD) (Hruska et al., 2008). GBA was
first found to be associated with PD due to a high incidence of
PD in both GD patients and heterozygous GBA carrier family
members (Tayebi et al., 2003). Approximately 5%–10% of PD
patients carry a heterozygous GBA mutation, making GBA vari-
ants the most common genetic risk factors for PD. The GBA-
N370S mutation is the most common GBA risk variant, and
patients have a clinical presentation similar to idiopathic PD
(Beavan and Schapira, 2013).
Understanding the molecular basis of neurodegenerative dis-
ease has been hindered by the inaccessibility of live vulnerable
human neurons from patients. The advent of induced pluripotent
stem cell (iPSC) technology enables the study of patient-derived
dopamine neurons from PD patients retaining genetic risk vari-
ants. Work with iPSC-derived dopamine neurons from PD pa-
tients carrying GBA (Fernandes et al., 2016; Scho¨ndorf et al.,
2014) or leucine-rich repeat kinase 2 (LRRK2) mutations (Sa´n-
chez-Dane´s et al., 2012) has revealed deficits in protein homeo-
stasis via the endoplasmic reticulum (ER), autophagic, and
lysosomal pathways. However, iPSC-derived neuronal cultures
often contain cellular heterogeneity, confounding gene expres-
sion profiling of a specific cell type.
Recently, we developed a method to obtain pure populations
of iPSC-derived dopamine neurons by fluorescence-activated
cell sorting (FACS), which we used to profile gene expression
in PD LRRK2-G2019S iPSC-derived dopamine neurons (Sandor
et al., 2017). Nonetheless, cellular heterogeneity remains, even
within a purified population, as individual cells are unlikely to
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Figure 1. Bulk RNA-Seq Analysis Confirms Purification of iPSC-Derived Dopamine Neurons and Identifies 247 DE Genes between Control
and PD GBA-N370S Patients Enriched for Genes in Pathways of Neuronal Function
(A) Schematic of sorting the tyrosine hydroxylase-positive (TH+) iPSC-derived dopamine neurons from three controls and three PD GBA-N370S
patients displaying a FACS plot identifying live/TH+ cells for sorting into bulk collection and into 96-well plates for single-cell RNA sequencing (gray wells
indicate blank wells). Bulk and single cells went through RNA extraction, cDNA synthesis, and amplification before undergoing sequencing and bioinformatic
analysis.
(legend continued on next page)
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experience the same gene-driven perturbation synchronously.
Bulk gene expression profiling across thousands of cells pro-
vides only a population average, obscuring that cells may be at
different points in one or more disease-relevant processes. By
contrast, profiling gene expression within individual cells can
exploit population heterogeneity, distinguishing distinct cell sub-
populations and discerning the progression of cells through the
disease-relevant processes being modeled (Reid and Wernisch,
2016). Our FACS-based purification method for dopamine
neurons is readily applicable to plate-based deep single-cell
profiling (Picelli et al., 2013).
Here, we applied bulk and deep single-cell gene expression
profiling to purified populations of iPSC-derived dopamine neu-
rons from three PD patients carrying the GBA-N370S variant.
Unique to a single GBA-N370S patient, we identified increased
activation of the signal recognition particle pathway. This molec-
ular stratification was validated by clinical follow-up, which
confirmed a revised diagnosis of progressive supranuclear palsy
for that patient, who was removed from further downstream
analysis.
Combining bulk and single-cell expression profiles, we identi-
fied a robust set of 60 genes whose expression captured an axis
of variationbetweencells fromcontrols and the remaining twoPD
GBA-N370S patients. Aligning individual cells across this axis
generated a pseudotemporal profile along which the sequence
of changes in the expression of individual genes could be in-
ferred. Although variation in gene expression at the end of the
pseudotemporal profile was associated with an increase in ER
stress, previously characterized in PD, many early differentially
expressed (DE) genes were found to be downregulated by his-
tone deacetylase 4 (HDAC4), a class IIa histone deacetylase,
which acts as a transcriptional repressor that shuttles between
thenucleus and the cytoplasm.HDAC4was found tobemislocal-
ized to the nucleus in PD GBA-N370S iPSC-derived dopamine
neurons. Modulation of HDAC4 activity or localization reversed
the downregulation of the core set of DE genes and ameliorated
PD-related cellular phenotypes previously described in PDGBA-
N370S dopamine neurons, including ER stress, autophagic and
lysosomal perturbations, and increased a-synuclein release.
Finally, we demonstrated HDAC4 mislocalization and perturba-
tion of the same core set of DE genes in iPSC-derived dopamine
neurons from a subset of idiopathic PD cases. Our work demon-
strates how we can exploit cellular heterogeneity to reveal dis-
ease mechanisms and therapeutic targets.
RESULTS
Characterization and Purification of iPSC-Derived
Dopamine Neurons by FACS
Previously, we reported that iPSC-derived dopamine neurons
obtained from PD GBA-N370S patients exhibited increased ER
stress, autophagic and lysosomal perturbations, and elevated
a-synuclein release (Fernandes et al., 2016). To further investi-
gate variation in gene expression, which may underlie disease
processes, we sought to purify iPSC-derived dopamine neurons
from control and GBA-N370S patients and subject them to both
bulk and single-cell RNA sequencing (Figure 1A).
iPSC lines derived from three PD GBA-N370S patients and
three controls (Figure S1) were differentiated into dopamine
neurons, as previously (Kriks et al., 2011), with minor modifica-
tions (Beevers et al., 2017). All iPSC lines were successfully
differentiated, typically yielding dopaminergic neuronal cultures
40%–60% positive for tyrosine hydroxylase (TH), a marker of
dopamine neurons (Figure S2A). To isolate dopamine neurons
from the heterogeneous population of differentiated cells, neu-
rons were sorted by FACS as described (Sandor et al., 2017; Fig-
ure S2B). Approximately 35–40,000 TH+ neurons were purified
and collected from each of the three control and three PD
GBA-N370S samples, and RNA was extracted. There was no
significant difference in the number of cells collected for each
group (Figure S2C) or in extracted RNA quality by RNA integrity
(RIN) values of 9 for the bulk-collected FACS-purified samples
(Figure S2D).
Bulk RNA Sequencing of Purified iPSC-Derived
Dopamine Neurons Reveals Downregulated Genes
Associated with Synaptic Function and Development
Bulk RNA sequencing (RNA-seq) profiles of FACS-purified cells
showed increased expression of dopamine neuron marker
genes (Figure 1B), such as tyrosine hydroxylase (TH), dopa
decarboxylase (DDC), solute carrier family 18 member A1
(VMAT1), LIM homeobox transcription factor 1 alpha (LMX1A),
and dopamine receptor D2 (DRD2). Purified neurons lacked
expression of glutamatergic neuronal markers, including COUP-
TF-interacting protein 2 (CTIP2), N-methyl-D-aspartate receptor
subunit NR1 (NMDAR1), orthodenticle homeobox 1 (OTX1), and
T-box brain protein 1 (TBR1), confirming purification specifically
of dopamine neurons (Figure 1C).
DE analysis between the PD GBA-N370S and control lines
identified differences in gene expression patterns, with 247
genes DE at a 1% false discovery rate (FDR) (Figure 1D). Overall,
gene ontology (GO) enrichment analysis of the upregulated and
downregulated genes in PD GBA-N370S iPSC-derived dopa-
mine neurons highlightedDEof genes involved in neuronal devel-
opment, neuronal differentiation, and synaptic activity, whereas
zinc ion transport functions featured in the upregulated genes
(Du et al., 2017; Forsleff et al., 1999; Park et al., 2014; Figure 1E).
Single-Cell RNA-Seq Stratifies PD GBA-N370S Patients
Initial analyses of the 146 single-cell transcriptomic profiles
passing quality control (QC) demonstrated the same enrichment
of neuronal marker genes as the bulk transcriptional profiles,
although with individual cell gene dropouts typical of single-cell
data (Pierson and Yau, 2015; data not shown). Principal compo-
nent analysis (PCA) found that the transcriptional profiles of the
cells segregated by patient origin along both the second and
third components (Figure 2A). Notably, cellular transcriptional
variation attributed to dopamine neurons derived from one of
(B andC) Expression of dopamine neuron-specificmarkers (B) and the absence of glutamatergic markers (C) in the purified bulk iPSC-derived dopamine neurons.
(D) Volcano plot showing 247 genes DE between GBA-N370S PD versus control identified by DESeq2 (FDR 1%).
(E) GO enrichment analysis of the upregulated and downregulated genes in PDGBA-N370S patients highlights DE of genes involved in neuronal development and
synaptic activity.
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Figure 2. Single-Cell RNA-Seq Stratification Identifies iPSC-Derived Dopamine Neurons from GBA3 as Significantly Different from Both PD
Patient and Control Neurons
(A) Transcriptome PCA analysis resolves GBA3 neurons (yellow) from the remaining two PD GBA-N370S patients and three controls.
(B) Over-dispersion analysis identifies a subset of genes that vary more than expected due to technical fluctuations in the dataset alone.
(C) Heatmap of the single-cell RNA-seq samples identifies an enrichment in the endoplasmic reticulum (ER) signal recognition particle (SRP) pathway in GBA3.
(D) Expression in log2 (TPM+1) of three genes (RPS12, RPS17, and RPS6) prioritized from those significantly DE within the SRP pathway between GBA3 and
controls 1, 2, and 3 and GBA1 and 2. DE analysis was performed using a two-sided Wilcoxon signed-rank test on all genes in the SRP pathway.
(E) The upregulation of the three selected genes involved in this pathway was confirmed in iPSC-derived dopamine neurons differentiated from three iPSC clones
of GBA3 compared to the three original controls and two PD GBA-N370S patients (GBA1 and 2), plus a fourth PD GBA-N370S patient (GBA4). Data are rep-
resented as mean ± SD (**p < 0.01; ***p < 0.001; ****p < 0.0001).
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the PD GBA-N370S patients (referred to as ‘‘GBA3’’) was repre-
sented by the third principal component (Figure 2A). Over-
dispersion analysis used to identify genes that varied more
than can be expected due to the inherent technical variation in
the dataset (Brennecke et al., 2013) observed 143 genes
(0.6%) as significantly over-dispersed at 5% FDR (Figure 2B).
A GO enrichment analysis on the over-dispersed genes identi-
fied the signal recognition particle (SRP)-dependent co-transla-
tional protein targeting to membrane pathway and related
processes as driving this variation.
The separation of GBA3 dopamine neurons along the third
principal component, and the large variation in a small set of
genes belonging to one pathway, prompted concerns that a sin-
gle sample could be driving the variation in gene expression be-
tween the PD GBA-N370S cases and controls. The expression
of genes belonging to the SRP-dependent co-translational pro-
tein targeting to membrane pathway strikingly demonstrated
increased activation in the GBA3 patient alone, who clustered
apart from all other case and control samples (Figure 2C).
Expression analysis of three genes in this pathway—ribosomal
protein S12 (RPS12), ribosomal protein S17 (RPS17), and ribo-
somal protein S6 (RPS6)—confirmed the upregulation in this
pathway to be specific to patient GBA3 (Figure 2D).
Expression of the same three genes was confirmed by qRT-
PCR in iPSC-derived dopamine neurons generated from the
original GBA3 iPSC line, two further iPSC lines from the GBA3
patient, the three controls, the two other original GBA patients,
and an additional fourth PD GBA-N370S patient (GBA4; Fig-
ure 2E). Comparison of the three GBA3 patient lines with the
three controls and GBA patients 1, 2, and 4 confirmed elevation
of the SRP-dependent co-translational protein targeting to
membrane pathway to be specific to GBA3, proposing a molec-
ular stratification of the patients used in this study.
Although all the patients in our study fulfilled UK Brain Bank
diagnostic criteria for clinically probable PD at presentation,
longitudinal clinical follow-up allows the diagnosis to be re-
viewed in light of disease progression and subsequent medica-
tion response. GBA patients 1, 2, and 4 presented at an early
stage with akinetic-rigid parkinsonism and maintained a good
levodopa response for their first five years of treatment without
significant falls or dementia. In contrast, patient GBA3 pre-
sented with akinetic-rigid parkinsonism, failed to respond to
standard medication (600 mg levodopa with benserazide
150 mg daily), and presented with early dementia and frequent
falls two years after initial PD diagnosis. A supranuclear gaze
palsy with dysarthria was then noted, and the patient received
a revised clinical diagnosis of progressive supranuclear palsy
(PSP). The stratification of PSP from PD among these GBA-
N370S carriers by single-cell profiling of their iPSC-derived
dopamine neurons is therefore consistent with the clinical
stratification and reveals a potential disease-relevant pathway
for PSP.
A Functionally Enriched Gene Set Defines a
Pseudotemporal Axis of PD GBA-N370S iPSC-Derived
Dopamine Neuron Gene Expression Variation
Upon removal of GBA3 from the analysis, we observed minimal
changes in the set of genes found to be DE (Figure S3). Analysis
of the transcriptomes of individual dopamine neurons broadly
segregated along the second principal component from a higher
concentration of control cells to a higher concentration of PD
GBA-N370S case cells (Figure S4A). We hypothesized that the
case-control divergence along this component reflected cells
that were at varying points in a common disease-related pro-
cess, with GBA1 and GBA2 neurons that were more control-
like being at an earlier point in the same process than GBA1
and GBA2 dopamine neurons that were less control-like. Our
approach is comparable to the idea of ‘‘pseudotime’’ in the
context of cellular differentiation (Haghverdi et al., 2016; Ji and
Ji, 2016; Reid and Wernisch, 2016).
As cells segregated by case-control status along the second
principal component, there was a possibility the data simply rep-
resented two distinct cell types with the apparent continuum due
to transcriptional noise. To test this hypothesis, we repeated
principal-component analysis on the GBA-N370S iPSC-derived
dopamine neurons alone and found a remarkable correlation of
the second principal component when all cells are included (Fig-
ure S4C). Therefore, the transcriptional heterogeneity at the sin-
gle-cell level represents a continuous disease axis from case to
control.
We next sought to identify a core set of genes consistently per-
turbed across both bulk RNA-seq and the single-cell transcrip-
tomic signature. This core set was identified as the intersection
of two gene sets from the analysis: (1) those DE in bulk RNA-
seq using DESeq2 after the removal of GBA3 (at 5% FDR) and
(2) those DE across PC2 using switchde (at 5% FDR; Campbell
and Yau, 2017; Figure S4B). We further refined this set to include
only those additionally identified as discriminating marker genes
after clustering the single-cell RNA-seq data using SC3 (Kiselev
et al., 2017). By combining genes found through both bulk and
single-cell DE as well as single-cell clustering (STAR Methods),
we identified a core set of 60 genes, 52 of which were consis-
tently downregulated and 8 of which were consistently upregu-
lated in PD GBA-N370S iPSC-derived dopamine neurons
(Figure S4B).
To validate that our core set of 60 genes were functionally
convergent, we assessed the functional similarity between these
genes within a phenotypic linkage network, as compared to
known PD genes and a random background set controlled for
the relevant core set gene properties (STAR Methods; Figures
S4D, S4E, and 3B).We found significant enrichment of functional
similarity within the 60-gene set compared to background genes
(p < 2.6e16; Figure 3B). Strikingly, we also found a significant
enrichment between the 60 genes and a set of known PD genes
(Figure 3B).
Within the set of 60 DE genes, those downregulated early in
the proposed case-control axis include genes implicated in
neuronal function (g-synuclein [SNCG], brain-derived neurotro-
phic factor [BDNF], and dopamine receptor D2 [DRD2]); genes
involved in microtubule-associated protein tau (MAPT) splicing,
microtubule function and formation, and neurite and axonal
outgrowth; genes involved in protein secretion and trafficking;
and protein kinase C (PKC) pathway genes. Genes identified
as upregulated late in the process include the ER stress genes
protein disulfide isomerase family member 6 (PDIA6), FK506
binding protein 9 (FKBP9), and ER oxidoreductase 1 alpha
(ERO1A). The upregulation of ER stress genes is consistent
with our previous findings, in which ER stress was increased in
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Figure 3. Pseudotime Analysis Temporally Orders the Core Set of 60 Functionally Similar GenesDE in Both the Bulk and Single-Cell RNA-Seq
between Control and PD GBA-N370S Patients
(A) Refined transcriptomic disease axis analysis of the core gene set of 60 genes. The control-disease single-cell transcriptomic axis was re-inferred with the 60
genes alone using a parametric factor analysis model that associated each gene with a point along the axis at which it was upregulated or downregulated.
(B) The phenotypic linkage network demonstrates a higher functional similarity of the 60-gene set with each other compared to a background control set
(p < 2.2e16). This higher functional similarity was also identified between the 60-gene set and a group of known PD loci, compared to a background control set
(p = 8.52e08). The high functional similarity of PD genes to each other is used as a positive control.
(C) Along the axis of disease, the downregulation of HDAC4-controlled genes (PRKCB, RTN1, ATP1A3, and TSPAN7) at 22 DIV precedes the upregulation of ER
stress genes (ERO1A, FKBP9, and PDI) at 38 DIV. Data are represented as mean ± SD (*p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001). The locations of the
HDAC4 and ER genes analyzed from the core 60 set are marked on (A).
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iPSC-derived dopamine neurons from PD GBA-N370S patients
(Fernandes et al., 2016).
We further refined the single-cell transcriptomic axis of 60
genes using a recent Bayesian approach that learns transcrip-
tomic trajectories directly from pre-specified genes using sin-
gle-cell expression data. Based on nonlinear factor analysis,
this approach models a small gene set in terms of ‘‘switch-
like’’ upregulation or downregulation along the latent (pseudo-
time) axis, jointly inferring the pseudotimes along with all model
parameters. Crucially, it probabilistically assigns a position along
the axis associated with the upregulation or downregulation of
each of the 60 genes, and we can anchor the direction of the
axis as proceeding from those GBA1 and GBA2 iPSC-derived
dopamine neurons that are most similar to controls. We hypoth-
esize that this axis represents the continuous progression of
these cells through amodeled disease-relevant process, moving
from a more control-like state to a more PD-relevant disease
state, and where the order of gene regulatory variation along
this axis reflects this modeled disease process (Figure 3A).
Analysis of the core set of 60 DE genes using ingenuity
pathway analysis (IPA) (QIAGEN) identified histone deacetylase
4 (HDAC4) as a repressor of a set of genes downregulated early
in the pseudotemporal profile (Figure S5A). Although total levels
of HDAC4 protein were unchanged between controls and PD
GBA-N370S patients (Figure S5B), the downregulation of four
of the HDAC4-regulated genes (TSPAN7, ATP1A3, RTN1, and
PRKCB) in PD GBA-N370S patient-derived neurons was exper-
imentally confirmed (Figure S5C).
We next sought to validate the proposed temporal order of
gene expression events in the development of disease patho-
physiology in PD GBA-N370S neurons. qRT-PCR analysis of
TSPAN7, ATP1A3, RTN1, and PRKCB confirmed that these
four ‘‘early’’ genes, predicted to be downregulated by HDAC4,
are repressed early in the differentiation at 22 DIV (days
in vitro). The ‘‘late’’ genes (ERO1A, FKBP9, and PDIA6), pre-
dicted to be upregulated as part of a subsequent ER stress
response, typically increase in expression post-22 DIV, with all
three increased at 38 and 48 DIV (Figure 3C).
HDAC4 Is Mislocalized to the Nucleus and Participates
in the Repression of Gene Expression in PD GBA-N370S
iPSC-Derived Dopamine Neurons
HDAC4, a class IIa histone deacetylase, shuttles between the
cytoplasm and the nucleus, where it acts as a transcriptional
repressor. We observed an increase in nuclear localization of
HDAC4 in PD GBA-N370S iPSC-derived dopamine neurons
compared to controls at DIV 45, consistent with the downregula-
tion of HDAC4 controlled genes within our set of 60 genes (Fig-
ure 4A). This HDAC4 nuclear mislocalization was not observed
in iPSC-derived non-dopaminergic neurons of PD GBA-N370S
patients (Figure S6).
Modulating HDAC4 Localization or Activity Corrects the
Downregulation of HDAC4-Repressed Genes and
Ameliorates ER Stress Phenotypes
To examine the effect of HDAC4 repression on the set of down-
regulated genes, we used four modulators of HDAC4 activity or
localization, currently in clinical use for unrelated conditions.
Tasquinimod is an allosteric inhibitor of the association of
HDAC4 with the nuclear N-Cor/HDAC3-associated repressor
complex (Isaacs et al., 2013), and okadaic acid (OA), cantharidin,
and LB-100 (LB-100) all inhibit protein phosphatase 2 (PP2A)-
mediated dephosphorylation of HDAC4, which reduces its nu-
clear localization (Gordon et al., 2015; Paroni et al., 2008; Pei
et al., 2016).
Treatment of PD GBA-N370S iPSC-derived dopamine neu-
rons with each of the three PP2A inhibitor compounds reduced
the nuclear localization of HDAC4, correcting HDAC4 mislocali-
zation in GBA-N370S dopamine neurons to that of controls
(Figure 4B). The addition of the HDAC4 allosteric inhibitor tasqui-
nimod did not reduce the HDAC4 nuclear localization (Figure 4B)
consistent with its mode of action, which does not involve
HDAC4 relocalization. We next examined the impact on gene
expression phenotypes of treating iPSC-derived dopamine neu-
rons with the HDAC4 modulators. Treatment with all four com-
pounds corrected, or even reversed, the reduction in expression
of all four HDAC4-controlled genes reduced early in the pseudo-
temporal axis (PRKCB, RTN1, ATP1A3, and TSPAN7) in PD
GBA-N370S iPSC-derived dopamine neurons at DIV 45 (Fig-
ure 5). Furthermore, compounds ameliorated the increase seen
in the three ER stress genes (ERO1A, FKBP9, and PDI), late
in the pseudotemporal axis, at the RNA and protein level (Fig-
ures 5 and S7A).
HDAC4 Modulation Corrects Perturbations in the
Autophagy and Lysosomal Pathway in PD GBA-N370S
iPSC-Derived Dopamine Neurons
In addition to increased ER stress, we have previously observed
perturbations in the autophagic and lysosomal pathway and
increased release of a-synuclein in PD GBA-N370S iPSC-
derived dopamine neurons (Fernandes et al., 2016). Treating
PD GBA-N370S iPSC-derived dopamine neurons with the
HDAC4 allosteric inhibitor tasquinimod or the representative
PP2A inhibitor cantharidin corrected the increase in autophago-
some number assessed by LC3-II levels (Figure 6A) through
decreased autophagic induction rather than increasing flux (Fig-
ures S7B–S7D), reduced the increase in lysosomal accumulation
measured by LAMP1 (Figures 6B and 6C), increased lysosomal
activity (Figure 6D), and reduced the increased release of a-syn-
uclein into the extracellular medium (Figure 6E).
Nuclear Mislocalization of HDAC4 and Related
Perturbations in Gene Expression Are Observed in
Idiopathic PD Cases
To address whether HDAC4 mislocalization is a disease mech-
anism relevant to PD beyond carriers of GBA mutations, we
examined HDAC4 mislocalization and perturbation of gene
expression in dopamine neurons differentiated from iPSC lines
generated from four idiopathic PD cases and three age-
matched controls. An increase in HDAC4 nuclear localization
was observed in iPSC-derived dopamine neurons from two of
the four idiopathic PD cases (Figures 7A and 7B). Furthermore,
the reduction of expression of the HDAC4-regulated genes
TSPAN7, ATP1A3, RTN1, and PRKCB, and the upregulation of
the ER stress genes ERO1A, PDIA6, and FKBP9, was observed
in iPSC-derived dopamine neurons from the same two idio-
pathic PD cases, which exhibited HDAC4 mislocalization (Fig-
ures 7C and 7D).
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DISCUSSION
Applying cell type purification and a combination of bulk and sin-
gle-cell gene expression profiling to iPSC-derived dopamine
neurons from three GBA-N370S patients, our study identified
disease-distinguishing molecular etiologies and revealed a tem-
poral ordering of gene expression variation that proposed a role
for the transcriptional regulator HDAC4 in upstream variation.
The pharmacological modulation of HDAC4 activity or localiza-
tion confirmed this finding by the rescue of downstream expres-
sion variation and correction of cellular phenotypes previously
shown in this model of PD.
Our FACS-based purification method is well-suited to deep
single-cell profiling. Although the cell fixation necessary for sort-
ing creates a 30 bias in transcript coverage, our gene level
coverage was high, enabling subsequent studies. Cells can be
clustered post-sequencing according to their expression pro-
files, but the cellular heterogeneity in these cultures would
Figure 4. Modulation of PP2A Activity Corrects HDAC4 Nuclear Mislocalization in PD GBA-N370S iPSC-Derived Dopamine Neurons
(A) Cytoplasmic and nuclear localization of HDAC4 in control and PD GBA-N370S dopamine neurons shown by immunofluorescence at 45 DIV—TH, green;
HDAC4, red; DAPI, blue; HDAC4/DAPI nuclear colocalization, purple. The HDAC4 nuclear/cytoplasmic ratio is significantly increased in PDGBA-N370S patients.
Data are represented as mean ± SD (**p < 0.01).
(B) HDAC4 cellular localization in the presence or absence of tasquinimod (HDAC4 allosteric inhibitor) or okadaic acid, cantharidin, and LB-100 (PP2A inhibitors)
at 45 DIV—TH, green; HDAC, red; DAPI, blue; and HDAC4/DAPI nuclear colocalization, purple. The three PP2A inhibitors correct HDAC4 nuclear mislocalization
in PDGBA-N370S patient-derived dopamine neurons compared to no treatment. In contrast, tasquinimod, a HDAC4 allosteric inhibitor, has no effect on HDAC4
localization. Data are represented as mean ± SD (****p < 0.0001).
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have halved our capture of dopaminergic neurons. Our robust
pseudotemporal analyses require only 150 single-cell tran-
scriptomic profiles to reveal disease-relevant perturbations.
Figure 5. Modulation of HDAC4 Activity or
Localization Corrects the Downregulation
of HDAC4-Controlled Genes in PD GBA-
N370S iPSC-Derived Dopamine Neuron Cul-
tures and Ameliorates PD GBA-N370S ER
Stress Phenotypes
Expression of four HDAC4-regulated genes
(TSPAN7, ATP1A3, RTN1, and PRKCB; bottom)
and three ER stress genes (PDIA6, FKBP9, and
ERO1A; top) at the RNA (left) and protein (right)
levels in the presence and absence of HDAC4-
modifying drugs tasquinimod, okadaic acid,
cantharidin, and LB-100 in PD GBA-N370S and
control patient-derived neurons at 45 DIV. The
upregulation of HDAC4-repressed genes in PD
GBA-N370S iPSC-derived dopamine neurons by
all four compounds was accompanied by a
decrease in ER stress. Data are represented as
mean ± SEM (*p < 0.05, **p < 0.01, ***p < 0.001,
and ****p < 0.0001).
Beyond cell-type heterogeneity, our
study exploited significant intra-culture
heterogeneity to unpick the disease pro-
cesses being modeled. First, we identi-
fied a distinct molecular perturbation
present in iPSC-derived dopamine neu-
rons generated from GBA-N370S pa-
tient 3 (GBA3). Despite an initial diag-
nosis of PD and possessing a genetic
variant strongly associated with PD,
this patient’s cellular profile prompted a
clinical reassessment, leading to the
revised diagnosis of PSP. Although
superficially similar in clinical presenta-
tion, PSP is a tauopathy with a cellular
pathophysiology distinct to the a-synu-
cleinopathy PD. Each of this patient’s
single-cell profiles proved an effective
technical replicate in the analyses.
Profiling this patient’s cells revealed a
distinct perturbation, which was further
validated in two additional iPSC-derived
dopamine neuron lines from the same
patient.
A second source of cellular heteroge-
neity is the varying progression of each
cell through the same disease process
over time. Although a bulk expression
profile averages across the cellular
population, obscuring variation, a single-
cell approach is able to exploit this
heterogeneity and reveals insights into
dynamic processes across a pseudotem-
poral axis. The ability to infer the temporal
nature of disease progression allowed
us to explore the relationship between early biological changes
in gene expression and their influence on later disease
phenotypes.
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We identified HDAC4 as a master regulator of a number of
genes downregulated early in the disease axis. Unlike class I
HDACs, which reside permanently in the nucleus, HDAC4 acts
as part of the HDAC4/N-CoR/HDAC3 complex that shuttles be-
tween the cytoplasm and the nucleus, repressing the expression
of genes important in synaptic function and neuronal health. Un-
der normal conditions, phosphorylated HDAC4 is retained in the
cytoplasm, but upon dephosphorylation of the Ser298 residue
by the catalytic subunit of PP2A, HDAC4 relocalizes to the nu-
cleus. Although HDAC4 was not DE in PD GBA-N370S patient-
derived dopamine neurons compared to controls, an increase
in the nuclear-to-cytoplasmic ratio of HDAC4 was identified,
consistent with the downregulation of DE genes in the core set
under the transcriptional control of HDAC4.
We therefore hypothesize that downregulation of HDAC4-
controlled genes due to the mislocalization of HDAC4 in the nu-
cleus early in the disease may contribute to driving ER stress
later in neurodegeneration. For example, mutations in the gene
ATP1A3, which is downregulated by HDAC4, cause a rare
rapid-onset dystonia-parkinsonism and is linked to altering intra-
cellular calcium levels, which could impact on the ER, the prin-
cipal intracellular store of calcium (Blanco-Arias et al., 2009).
Similarly, PRKCB participates at mitochondrial-ER-associated
membrane (MAM) sites, playing a crucial role in the phosphory-
lation of the p66Shc protein, which is involved in the regulation of
calcium homeostasis between these two organelles (Pinton and
Rizzuto, 2008).
Deficits in calcium signaling may also cause the increased nu-
clear localization of HDAC4 in PD GBA-N370S patient-derived
dopamine neurons. HDAC4 is known to regulate genes involved
in synaptic activity and memory and neuronal health (Sando
et al., 2012). As cytoplasmic retention of class IIa HDACs re-
quires calcium-dependent phosphorylation through calcium
and/or calmodulin-dependent kinases, elevated cytoplasmic
calcium caused by influx through voltage-gated ion channels in
highly active neurons maintains HDAC4 cytoplasmic retention.
Conversely, loss of synaptic excitation due to neurodegenera-
tion may contribute to HDAC4 nuclear localization and repres-
sion of genes that promote neuronal survival. PD GBA-N370S
patient-derived dopamine neurons are known to exhibit impaired
cellular calcium homeostasis (Scho¨ndorf et al., 2014), and
low synaptic calcium levels in hippocampal and cerebellar
granule cell cultures triggered the shuttling of HDAC4 from
dendritic spines to the nucleus (Bolger and Yao, 2005; Chawla
et al., 2003).
Pharmacological modulation of HDAC4 activity or localization
corrected cellular phenotypes previously described in PD GBA-
N370S patient-derived dopamine neurons, alleviating ER stress
to reduce autophagic induction, suggesting HDAC4 as a thera-
peutic target for PD. All compounds tested are currently in clin-
ical development for unrelated conditions, principally cancer.
Decreased HDAC4 nuclear localization through increased phos-
phorylation and cytoplasmic retention was achieved through in-
hibition of PP2A. PP2A dephosphorylates multiple targets in
addition to HDAC4, including the major neurodegenerative pro-
teins tau and a-synuclein, which may prevent prolonged clinical
use. More interesting is the use of the allosteric inhibitor tasqui-
nimod to inhibit formation of the HDAC4/N-CoR/HDAC3 repres-
sion complex by locking HDAC4 in an inactive form (Isaacs et al.,
2013). Tasquinimod has been tested through phase II and III clin-
ical trials to treat prostate cancer with a good safety profile
(Armstrong et al., 2013; Sternberg et al., 2016). The compound
A B
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Figure 6. Modulation of HDAC4 Activity or
Localization Rescues Deficits in the Auto-
phagic and Lysosomal Pathway and Re-
duces a-Synuclein Release in PD GBA-
N370S iPSC-Derived Dopamine Neurons
(A and B) Modulation of HDAC4 activity by allo-
steric inhibition of HDAC4 (tasquinimod) or inhibi-
tion of PP2A (cantharidin) rescues the increase
in autophagosomal (LC3-II; A) and lysosomal
(LAMP1; B) compartments seen by western blot in
PD GBA-N370S patient iPSC-derived neurons
compared to controls.
(C) The reduction of lysosomes in PD GBA-N370S
iPSC-derived dopamine neurons treated with
tasquinimod or cantharidin was confirmed by a
decrease in lysosome punctae by immunofluo-
rescence.
(D) Modulation of HDAC4 increases lysosomal
activity in PD GBA-N370S iPSC-derived neurons
measured by DQ-BSA cleavage.
(E) Tasquinimod or cantharidin reduces the in-
crease in a-synuclein release seen in PD GBA-
N370S patient-derived neurons compared to
controls.
Data are represented as mean ± SEM (*p < 0.05,
**p < 0.01, and ***p < 0.001).
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is well-tolerated in patients for up to 3 or 4 years with few dose
interruptions or reductions. HDAC4 is considered to be a poten-
tial therapeutic target in Huntington’s disease (HD), as a hetero-
zygousHdac4+/ background rescued neuronal function in a HD
mouse model (Mielcarek et al., 2013) but has yet to be explored
therapeutically in PD.
To investigate whether these disease mechanisms are rele-
vant to PD beyond carriers of GBA mutations, we extended
our study to include iPSC-derived dopamine neurons from idio-
pathic PD cases. Remarkably, we found that increased HDAC4
nuclear localization was seen in iPSC-derived dopamine neu-
rons from two of four idiopathic PD cases. Furthermore, the
same perturbation of expression, being the downregulation of
HDAC4-regulated genes TSPAN7, ATP1A3, RTN1, and PRKCB
and the upregulation of ER stress genes ERO1A, PDIA6, and
FKBP9, was seen in the same two idiopathic PD cases exhibiting
HDAC4mislocalization. These data show that findings fromGBA
PD extrapolate to a subset of idiopathic PD cases. Heterogeneity
between idiopathic patients is expected in a disease with com-
plex polygenic inheritance, leading to a variable level of cell-
autonomous effects in different individuals, and one might
expect the genetic contribution to be greater in some idiopathic
Figure 7. Nuclear Mislocalization of HDAC4 and Related Perturbations in Gene Expression Are Observed in Idiopathic PD Cases
(A) Cytoplasmic and nuclear localization of HDAC4 in control and idiopathic PD iPSC-derived dopamine neurons shown by immunofluorescence at 45 DIV—TH,
green; HDAC4, yellow; DAPI, blue.
(B) The HDAC4 nuclear/cytoplasmic ratio is significantly increased in two of the four idiopathic PD patients. Data are represented as mean ± SEM (*p < 0.05).
(C and D) A (C) decrease in the expression of HDAC4-controlled genes: TSPAN7; ATP1A3; RTN1; and PRKCBI and an (D) increase in the expression of ER stress
genes: ERO1A; PDIA6; and FKBP9 is observed in the same two idiopathic PD cases that display HDAC4 mislocalization.
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patients than others. Our findings are consistent with recent
studies (Hsieh et al., 2016; Sa´nchez-Dane´s et al., 2012; Nena-
sheva et al., 2017; Tolosa et al., 2018; George et al., 2018), which
have found cellular phenotypes or transcriptomic perturbations
in iPSC-derived dopamine neurons from idiopathic PD patients.
Overall, our work applied high-resolution single-cell analysis to
iPSC-based disease models, exploiting the cellular heterogene-
ity present even within a purified single cell type, in this case,
iPSC-derived dopamine neurons from PD patients. We have
shown the disease process to be a dynamic event and identified
HDAC4 as a key regulator of the early molecular changes that
lead to late pathological processes. Our approach is applicable
to other diseases as a means to uncover disease mechanisms
and discover potential therapeutic targets.
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STAR+METHODS
KEY RESOURCES TABLE
REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Tyrosine hydroxylase Millipore RRID: AB_90755
Beta-III tubulin (TUJ1) Covance RRID: AB_2313773
HDAC4 Abcam RRID: AB_298903
b-actin Abcam RRID: AB_2305186
PDI Cell signaling RRID: AB_2156433
FKBP9 Abcam RRID: AB_10562617
Ero1-La Cell signaling RRID: AB_823683
TSPAN7 Novus biologicals RRID: AB_11035060
Na+/K+-ATPasea3 (ATP1A3) Santa cruz RRID: AB_10848453
Rtn1/2 Santa cruz RRID: AB_2183564
PRKCB ProSci Cat#43-319
LAMP1 Santa cruz RRID: AB_626853
LC3B Sigma RRID: AB_796155
TRA-1-60 Biolegend RRID: AB_1186144
Nanog Cell signaling RRID: AB_10694485
Biological Samples
OX1-19/SFC841-03-1/2 EBiSC UOXFi004-B/ STBCi044-B
JR053-1/6 EBiSC UOXFi005-A/ UOXFi005-B












Chemicals, Peptides, and Recombinant Proteins
ROCK inhibitor (Y27632 dihydrochloride) Bio-Techne Cat#1254
Tasquinimod Tocris Cat#S7617
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Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
TGFb3 Peprotech Cat#100-36E
DAPT Abcam Cat#ab120633
Ascorbic acid Sigma Cat#A4544
(db)-cAMP Sigma Cat#D0627
hESC-qualified Matrigel Corning Cat#354277
DQ BSA Red Thermo Fisher Scientific Cat#D12051
NucBlue Live ReadyProbes Thermo Fisher Scientific Cat#R37605
Critical Commercial Assays
Cytotune v1 Sendai Reprogramming kit Thermo Fisher Scientific A13780-01
Cytotune v2 Sendai Reprogramming kit Thermo Fisher Scientific A16517
b-Actin qPCR Control Kit Eurogentec SR-CL004-005
Human-HT-12-v4 expression BeadChip Kit BD BD-103-0204
All-Prep DNA/RNA Mini kit QIAGEN 80204
RNeasy FFPE kit QIAGEN Cat#73504
RNA 6000 pico kit Agilent Cat#5067-1513
Quant-iT RiboGreen RNA kit Thermo Fisher Scientific Cat#R11490
Nextera XT DNA Library Prep Kit Illumina Cat#FC-131-1096
RNeasy Micro kit QIAGEN Cat#74004
Superscript III reverse transcriptase kit Thermo Fisher Scientific Cat#18080093
Fast SYBR green master mix Thermo Fisher Scientific Cat#4385612
aSyn extracellular release MSD kit Meso Scale Discovery Cat#K151TGD-2
Deposited Data
Raw RNA-seq data ArrayExpress ArrayExpress: E-MTAB-7303
Software and Algorithms
Harmony Perkin Elmer N/A
GenomeStudio Illumina N/A
Karyostudio Illumina N/A
TrimGalore v0.4.1 (Krueger, 2015) https://www.bioinformatics.babraham.ac.
uk/projects/trim_galore/
Kallisto v0.42.5 (Bray et al., 2016) https://pachterlab.github.io/kallisto/
Picard 2.0.1 (Picard Toolkit, 2018) https://broadinstitute.github.io/picard/
HISAT2 (Kim et al., 2015) https://ccb.jhu.edu/software/hisat2/
index.shtml
Tximport 1.4.0 (Soneson et al., 2015). https://bioconductor.org/packages/
release/bioc/html/tximport.html
Scater 1.8.0 (McCarthy et al., 2017) https://bioconductor.org/packages/
release/bioc/html/scater.html
Cellity 1.8.0 (Ilicic et al., 2016) https://bioconductor.org/packages/
release/bioc/html/cellity.html
DESeq2 (Love et al., 2014), https://bioconductor.org/packages/
release/bioc/html/DESeq2.html
goseq (Young et al., 2010) https://bioconductor.org/packages/
release/bioc/html/goseq.html
The R project for statistical computing R Development Core Team, 2008 https://www.r-project.org/
switchde 1.6.0 (Campbell and Yau, 2017) https://bioconductor.org/packages/
release/bioc/html/switchde.html
Ouija 0.99.0 (Campbell and Yau, 2017) https://github.com/kieranrcampbell/ouija/
scran 1.8.2 (Lun et al., 2016) https://bioconductor.org/packages/
release/bioc/html/scran.html
Phenotypic Linkage Network (Honti et al., 2014). https://github.com/csandorfr/AP-PLN
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CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contacts, Richard
Wade-Martins (richard.wade-martins@dpag.ox.c.uk).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
iPSC lines and participation recruitment
Participants were recruited to the Discovery clinical cohort through the Oxford Parkinson’s Disease Centre and gave signed informed
consent to mutation screening and derivation of iPSC lines from skin biopsies (Ethics committee: National Health Service, Health
Research Authority, NRESCommittee South Central, Berkshire, UK, REC 10/H0505/71). All the patients included in our study-fulfilled
UK Brain Bank diagnostic criteria for clinically probable PD at presentation (Hughes et al., 1992). GBA-N370S PD patients 1, 2 and 4
presented with akinetic-rigid parkinsonism, andmaintained a good levodopa-response for their first 5 years of treatment without sig-
nificant falls or dementia. GBA-N370S patient 3 presented with akinetic-rigid parkinsonism, failed to respond to good doses of oral
dopaminergic medication (600 mg levodopa, 150 mg benserazide daily), subsequently rapidly progressed more quickly with early
dementia and frequent falls two years later. The patient has a revised diagnosis of Progressive Supranuclear Palsy (PSP). Patients
with idiopathic Parkinson’s who met the UK Parkinson’s Disease Society Brain Bank (UKPDBB) criteria for the diagnosis of probable
idiopathic PD (Hughes et al., 1992) on examination by a neurologist were recruited from ongoing cohort studies at the University of
Oxford (UK) and the University of Lubeck (Germany) (Kasten et al., 2013). Patients with secondary parkinsonism due to head trauma
or medication use, or features of atypical parkinsonism syndromes, were excluded (Szewczyk-Krolikowski et al., 2014).
Subject details
Culture, reprogramming and characterization of primary fibroblasts
Low passage fibroblast cultures were established from participant skin punch biopsies, and these were reprogrammed either by
retroviral delivery or CytoTune-iPS Sendai Reprogramming kit (Thermo Fisher Scientific, version 1 or 2) as previously described (Fer-
nandes et al., 2016). Clones were transitioned to feeder-free culture in mTeSR medium (StemCell Technologies), on hESC-qualified
Matrigel-coated plates (BD), and passaged as cell clusters using 0.5 mM EDTA in PBS. Large batches were tested for mycoplasma
(Mycoalert, Lonza), QCed (see below) and frozen at p15-25. When thawing for experiments, 10 mM ROCK inhibitor (Y27632, Bio-
Techne) was added to promote initial survival and iPSC were passaged 1:2-3 using TryplE (Life Tech) with Y27632 during replating,
culturing for maximum two weeks’ post-thaw prior to differentiation to ensure consistency.
The following iPSC lines used in this study have been previously described: OX1-19 (vanWilgenburg et al., 2013), AH016-3/6 (San-
dor et al., 2017), SFC840-03, MK088-1, MK071-3, SFC834-03 (Fernandes et al., 2016) and SFC840-03-06 (Haenseler et al., 2017).
iPSC PD GBA lines, iPS MK082-26 and JR053-6, and idiopathic PD lines SFC077-03-04, SFC120-03-04, SFC844-03-12 and
SFC865-03-07 are characterized here (Figure S1). Control lines SFC067-03-01 and SFC156-03-01 are registered in hPSCreg,
with accompanying QC reports. Briefly, fluorescence activated cell sorting (FACS) for pluripotency markers TRA-1-60 (Biolegend)
and Nanog (Cell Signaling) was performed on a FACSCalibur (BD Biosciences).
Donor ID iPSC clone Study ID Genotype Age & gende Characterization
AH016 03/06 Control 1 wt/wt 80 M Sandor et al., 2017
JR053 06/01 Control 2 wt/wt 68 M This study
OX1 SFC841-03 19 01/02 Control 3 wt/wt 36 M Van Wilgenburg et al., 2013
SFC156-03 01 Control 4 wt/wt 75 M This study
SFC840-03 06 Control 5 wt/wt 67 F Haenseler et al., 2017
SFC067-03 01 Control 6 wt/wt 72 M This study
MK088 01 GBA 1 N370S/wt 46 M Fernandes et al., 2016
MK071 03 GBA 2 N370S/wt 81 F Fernandes et al., 2016
SFC834-03 03 GBA 3 N370S/wt 72 M Fernandes et al., 2016
MK082 26 GBA 4 N370S/wt 51 M This study
SFC077-03 04 Idiopathic PD 1 N/A 65 M This study
SFC844-03 12 Idiopathic PD 2 N/A 72 M This study
SFC120-03 04 Idiopathic PD 3 N/A 72 M This study
SFC865-03 07 Idiopathic PD 4 N/A 69 M This study
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Silencing of retroviral delivered reprogramming genes was assessed by quantitative RT-PCR using the following primers:
pMXsAS3200v2 TTA TCG TCG ACC ACT GTG CTG GCG mNanog forward primer GCT CCA TAA CTT CGG GGA GG. The b-Actin
qPCR Control Kit (Eurogentec) was used as control normalization. Clearance of Cytotune Sendai vectors was performed by RT-PCR
according to the manufacturer’s instructions. Analysis of pluripotency gene expression profile was performed using the Human-HT-
12-v4 expression BeadChip Kit (Illumina). Genome integrity was assessed applying the Illumina Human CytoSNP-12v2.1 beadchip
array or Illumina human OmniExpress24 on genomic DNA generated using the All-Prep kit (QIAGEN) and analyzed using
GenomeStudio and Karyostudio software (Illumina).
Generation and characterization of iPSC derived dopamine neurons
Six control (OX1-19/SFC841-03-01/02, JR053-6/1, AH016-3/6, SFC156-03-01, SFC840-03-06 and SFC067-03-01), four GBA-
N370S (MK088-1, MK071-3, SFC834-03-03 and MK082-26) patient lines and four idiopathic (SFC077-03-04, SFC844-03-12,
SFC120-03-04 and SFC865-03-07) patient lines were differentiated, as described previously (Kriks et al., 2011), with slight modifi-
cations (Beevers et al., 2017). Cells underwent 21 days of patterning and differentiation, were replated and matured for a further
5 weeks (60 DIV) when collected for flow cytometry. Control and PD GBA-N370S patient lines were successfully differentiated
into dopaminergic neurons, expressing beta-tubulin III (TUJ1) a neuronal marker and Tyrosine Hydroxylase (TH) a specific dopami-
nergic neuronal marker by immunofluorescence (Figure S2A). Treatment of iPSC-derived dopamine neurons with the HDAC4 modi-
fying compounds occurred at DIV 45 for 72 hours at the following concentrations: Tasquinimod (15uM), Okadaic acid (10nM), LB100
(1.25uM) and Cantharidin (250nM).
METHOD DETAILS
Purification of iPSC dopaminergic neurons by flow cytometry
Purification of iPSCderived dopaminergic neuronswas carried out as previously described (Sandor et al., 2017). At sorting each sam-
ple was first sorted into each row of a 96 well plate, into 2 ul of smart-seq 2 lysis buffer (0.2% triton x-100 and 2 U/ul RNase inhibitor),
so that all samples were on each 96 well plate for single cell RNA-sequencing. After 96 well plate sorting, the rest of the sample was
bulk collected for RNA extraction in preparation for bulk RNA-sequencing.
RNA preparation of bulk RNA-seq samples
RNA from bulk collected FACS sorted dopamine neurons was extracted using an FFPE RNA extraction kit (QIAGEN) as per manu-
facturer’s instructions, with minor modifications. RNA integrity analysis was analyzed using a 2100 bioanalyzer system and a RNA
6000 pico kit (Agilent). Concentration was obtained and confirmed utilizing two methods; the 2100 bioanalyzer system and a
Quant-iT RiboGreen RNA kit (Invitrogen), as per manufacturer’s instructions.
Smart-seq2, RNA library construction and sequencing
Single cells and RNA extracted from bulks were processed using the Smart-seq2 protocol (Picelli et al., 2013). cDNA samples were
prepared for sequencing using the Nextera XT DNA Library Prep Kit (Illumina) with our own in-house indexing primers (Lamble et al.,
2013). Libraries were pooled and sequenced using Illumina HiSeq4000 75bp paired-end sequencing.
RNA-seq read alignment and expression quantification
Single-cell and bulk RNA-seq data was processed identically. FASTQ files were trimmed using TrimGalore v0.4.1 on default settings.
Transcript expression levels were quantified using Kallisto v0.42.5 (Bray et al., 2016) against GRCh38 reference human transcrip-
tome. Additional quality control (QC) metrics were compiled by Picard 2.0.1 (https://broadinstitute.github.io/picard/) on BAM files
aligned to the human genome (GRCh38) using Hisat2 (Kim et al., 2015). Transcript level abundances were then summarized
to gene level estimates using tximport 1.4.0 (https://bioconductor.org/packages/release/bioc/html/tximport.html) (Soneson
et al., 2015).
Quality control of single-cell RNA-seq
Quality-control, visualization, and handling of single-cell data was performed using Scater (McCarthy et al., 2017). Cells belonging
to plates 3-6 were removed due to distinct clustering on reduced-dimensionality representations and low expression of
otherwise constitutively expressed genes. Further outliers were removed using Cellity (Ilicic et al., 2016) and subsequently any
cell expression GAPDH at a level below the maximum GAPDH expression in blank wells was further removed, leaving a total of
146 cells for analysis.
Differential expression analysis
Differential expression analysis on bulk RNA-seq was performed using DESeq2 (Love et al., 2014), including a covariate to account
for technical replicates. GO enrichment was performed using goseq (Young et al., 2010) and over-represented p values weremultiple
test corrected using the Benjamini-Hochberg procedure.
e4 Cell Stem Cell 24, 93–106.e1–e6, January 3, 2019
Single-cell pseudotime analysis
A PCA representation of the cells was computed using the prcomp function in the stats package in R using the 500 most variable
genes (in log expression space), the default in Scater. Single-cell differential expression analysis along PC2 was performed using
the R package switchde (Campbell and Yau, 2017). A further refined trajectory using the combined gene list along was computed
using Ouija.
Identification of pathway activation in GBA 3
Over-dispersion analysis was performed in the method identical to Brennecke et al. (2013) using the R package scran (Lun et al.,
2016) using ERCC spike-ins. A gene was designated as over-dispersed if the reported q-value < 0.05. GO analysis was performed
using the R package GOSeq (Young et al., 2010). Genes from the SRP-dependent co-translational protein targeting to membrane
pathway were selected for validation by performing a Wilcoxon rank-sum test for log2(TPM+1) expression in GBA3 cells compared
to controls and prioritized based on p value.
Phenotypic linkage network construction
To assess functional similarity and convergence of the core gene set we constructed a phenotypic linkage network (Honti et al.,
2014). We wished to assess the functional similarity of genes within the core set compared to a randomly sampled background dis-
tribution. The genes selected for the background distribution should match the overall expression pattern of the core set in these
iPSCs in order to account for the increased likelihood of functional similarities between genes randomly selected from the same
cell type. We first noted that the core set of genes exhibited high mean expression than average among the whole transcriptome.
We then fitted a gamma distribution to the mean log2(TPM+1) values of both the core gene set and all other genes in the transcrip-
tome (the core distribution and background distribution). Then for each gene not in the core gene set we calculated the probability of
observing the mean expression level under both models, and formed an unnormalized inclusion probability of the ratio of the density
of the observed expression given the core gene set distribution to the density of the observed expression given the background dis-
tribution. This can loosely be thought of as ‘‘howmany times more likely is it that a gene fits the core set distribution compared to the
background distribution.’’ To choose the background set of genes we then sampled 1000 genes from the transcriptome excluding
the core gene set, where the probability of a gene being selected was proportional to the un-normalized inclusion probability. The
resulting empirical distribution fitted well with the fitted core gene set distribution (Figure S4D). We subsequently constructed
a phenotypic linkage network as per Honti et al. (2014) using 1) the core set of genes, 2) the 1000 sampled background genes,
and 3) the genes SNCA, PARK2, PARK7, LRRK2, UCHL1, GBA, PINK1, ATP13A2, HTRA2, PLA2G6, VPS35, and EIF4G1. Links
were compared between different classes of genes using a one-sided Wilcoxon rank-sum test.
qRT-PCR, immunocytochemistry and western blot
For qRT-PCR experiments to validate RNA-Seq findings RNA was extracted from 12 well plates using Trizol (life technologies) and
purified using the RNeasy Micro kit (QIAGEN) as per manufacturer’s instructions. Quality and concentration were quantified using a
Nanodrop 1000 (Thermo Scientific). cDNA was synthesized using a superscript III reverse transcriptase kit (Life technologies) as per
manufacturer’s instructions. qRT-PCR was carried out using fast SYBR green mastermix and a StepOnePlus thermal cycler (Life
technologies). Primers used in this study can be found in Table S2.
For immunocytochemistry cells were fixed in 4% paraformaldehyde in 96 well plates (microClear 96 well plates, Greiner). They
were then blocked with 10% donkey serum (PBS/0.5% triton x) for 1 hour, incubated with the following antibodies; Tyrosine hydrox-
ylase (1:500Millipore AB1542), Beta-III tubulin (1:500 CovanceMMS 435P), HDAC4 (1:500 Abcam ab12171) and DAPI in 1% donkey
serum (PBS/0.5% triton x). Secondary antibodies were added in 1%donkey serum (PBS) for 1 hour. Cells werewashed and kept in 1x
PBS for imaging on the Opera Phenix (Perkin Elmer).
For western blotting cells were extracted from 12 well plates in RIPA buffer (Tris [50 mM, pH 8], sodium chloride [150 mM], sodium
dodecyl sulfate [SDS; 0.1%w/v], sodiumdeoxycholate [0.5%w/v] and nonidet-P40 [1%w/v]). Sampleswere denatured for 5minutes
at 100C. Protein separation was achieved using SDS polyacrylamide gel electrophoresis and transferred onto PVDF membrane.
Antibodies used as follows: Tyrosine hydroxylase (1:500 Millipore AB1542), b-actin (1:10,000 Abcam ab8227), PDI (1:500 Cell
signaling 3501), FKBP9 (1:500 Abcam ab91219), Ero1-La (1:500 Cell signaling 9956), TSPAN7 (1:250 Novus Biologicals NBP1-
90310), Na+/K+-ATPase a3 (1:500 Santa cruz sc-365744), Rtn1/2 (1:500 Santa cruz sc-71981), PRKCB (1:250 ProSci 43-319),
LAMP1 (1:500 Santa cruz sc-20011), LC3B (1:500 Sigma L7543), HDAC4 (1:500 Abcam ab12171).
DQ-BSA
DQ-BSA Red reagent was prepared according to manufacturer’s instructions. While remaining under treatment of the selected com-
pounds, iPSC-derived dopaminergic neurons were incubated with 30mg/mL DQ BSA Red and NucBlue Live ReadyProbes reagents
for 4 hours at 37C. Cells were washed with DPBS, replaced into fresh media and imaged on the Opera Phenix High Content
Screening System (Perkin Elmer).
a-synuclein release
Extracellular a-synuclein release was quantified as previously described (Fernandes et al., 2016). Briefly, conditioned media from
treated iPSC-derived neuronal cultures (100 ml) was collected at D45 and stored at 80C prior to analysis. a-synuclein release
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was quantified relative to a standard curve using an electrochemiluminescent assay (Meso Scale Discovery, MD, USA, Cat#
K151TGD-2) and a MESO QuickPlex SQ 120 instrument (Meso Scale Discovery). Extracellular a-synuclein release was normalized
relative to total protein content of cells, using a BCA assay.
QUANTIFICATION AND STATISTICAL ANALYSIS
For differences between more than two groups a two way-ANOVA analysis was used to test for the significance. Mean values ± SEM
are shown unless otherwise stated. P value for comparisons were adjusted for multiple comparisons using a Bonferroni correction.
Data was presented of 3 independent controls and patients, over three differentiations unless otherwise stated.
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